---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-041601"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2023-08-11T23:59:59+00:00"
generated_at: "2026-06-11T14:56:47.846262+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Pyxis Oncology Q2 net loss $15.9M; cash $144.1M; Apexigen deal on track for August close

## Summary
- Net loss $15.9M ($0.41/share) vs $25.6M ($0.79) in Q2 2022; loss narrowed on lower R&D and G&A.
- Cash and short-term investments $144.1M as of June 30, 2023; expected runway into first half of 2025.
- R&D expenses $11.4M (down from $17.2M YoY); G&A $6.7M (down from $8.6M YoY).
- Third dose cohort initiated in Phase 1 trial of ADC PYX-201; three European sites recruiting.
- Apexigen acquisition expected to close later in August 2023; sotigalimab development plan in Q4.

## SEC filing metadata
- accession: 0000950170-23-041601
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2023-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000095017023041601/0000950170-23-041601-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000095017023041601/pyxs-20230811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-041601
- JSON: https://secwatch.observer/filing/0000950170-23-041601.json
- Plain text: https://secwatch.observer/filing/0000950170-23-041601.txt

## Key facts
- Earnings Releases
  Pyxis Oncology, Inc. reported the quarter ended June 30, 2023 results: net income $15.9 million, EPS $0.41 per common share.
  - Period: the quarter ended June 30, 2023
  - Net income: $15.9 million
  - EPS: $0.41 per common share
  - Result: reported results
  source text: Net loss was $15.9 million, or $0.41 per common share, for the three months ended June 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782223/000095017023041601/0000950170-23-041601-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.